

Eff. Date: 1 June 2023

Version: 2.2

IFU: BCA-225 ILM2122

BCA-225 clone Cu-18

Instructions For Use

Specification:

Anti-BCA-225 antibody recognizes a human breast carcinoma associated glycoprotein BCA-225 (220-225kD). This protein differs in size and distribution from other breast carcinoma antigens. Unlike other antibodies against breast carcinoma antigens, this antibody does not react with benign or malignant colonic, stomach, prostate, liver, pancreas, thyroid, or parotid tissues. Adenocarcinomas of the lung, ovary and endometrium also stain with this antibody.

Availability:

Catalog No	Contents	Volume
ILM2122-C01	BCA-225	0,1 ml concentrate
ILM2122-C05	BCA-225	0,5 ml concentrate
ILM2122-C1	BCA-225	1,0 ml concentrate

Intended use: For Research Use Only

Clone: Cu-18

Species of origin: Mouse

Isotype: IgG1, Kappa

Control Tissue: Breast carcinoma, fallopian tube, or skin.

Staining: Cytoplasm

Immunogen: A synthetic peptide

Presentation: Purified antibody with 0.2% BSA and 15mM sodium azide.

Application and suggested dilutions:

Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

• paraffin embedded tissue section (dilution up to 1:50-1:100)

The optimal dilution for a specific application should be determined by the investigator.

Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

References:

- 1. Ma CK, et al. Am J Clin Pathol. 1993; 99:551-7.
- 2. Mesa-Tejada R, et al. Am J Pathol; 1988; 130:305-14.
- 3. Ansai S, et al. J Dermatol. 1994; 21:20-4.